Cited by

• [First-line Chemotherapy for Extensive-disease Small Cell Lung Cancer: 
A Network Meta-analysis].

  Chen Y, Chen L, Zhong D, Wang J, Peng L, Feng X. Chen Y, et al. Zhongguo Fei Ai Za Zhi. 2016 Apr 20;19(4):184-91. doi: 10.3779/j.issn.1009-3419.2016.04.02. Zhongguo Fei Ai Za Zhi. 2016. PMID: 27118645 Free PMC article. Chinese.
• Randomized phase 2 study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401).

  Tanaka H, Hasegawa Y, Fujita Y, Nakamura A, Kikuchi E, Kawai Y, Harada T, Watanabe N, Yokouchi H, Usui K, Saito R, Watanabe H, Masuda T, Fukuhara T, Kudo K, Honda R, Oizimi S, Maemondo M, Inoue A, Morikawa N. Tanaka H, et al. Thorac Cancer. 2021 Jul;12(14):2113-2121. doi: 10.1111/1759-7714.14048. Epub 2021 Jun 2. Thorac Cancer. 2021. PMID: 34076966 Free PMC article. Clinical Trial.
• Novel systemic therapies for small cell lung cancer.

  Rudin CM, Hann CL, Peacock CD, Watkins DN. Rudin CM, et al. J Natl Compr Canc Netw. 2008 Mar;6(3):315-22. doi: 10.6004/jnccn.2008.0026. J Natl Compr Canc Netw. 2008. PMID: 18377849 Free PMC article.
• Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer.

  Chiappori AA, Zheng Z, Chen T, Rawal B, Schell MJ, Mullaney BP, Bepler G. Chiappori AA, et al. J Thorac Oncol. 2010 Apr;5(4):484-90. doi: 10.1097/JTO.0b013e3181ccb27b. J Thorac Oncol. 2010. PMID: 20107425 Free PMC article.
• Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer.

  Chiappori AA, Williams CC, Gray JE, Tanvetyanon T, Haura EB, Creelan BC, Thapa R, Chen DT, Simon GR, Bepler G, Gabrilovich DI, Antonia SJ. Chiappori AA, et al. Cancer Immunol Immunother. 2019 Mar;68(3):517-527. doi: 10.1007/s00262-018-2287-9. Epub 2018 Dec 27. Cancer Immunol Immunother. 2019. PMID: 30591959 Free PMC article. Clinical Trial.